LCMS using a hybrid quadrupole time of flight mass spectrometer for impurity identification during process chemical development of a novel integrase inhibitor

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 1, 2010, Pages 78-83

  Novak, T J ^a   Grinberg, N ^b   Hartman, B ^a   Marcinko, S ^a   DiMichele, L ^a   Mao, B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Impurity identification; LCMS; Process development; QTof; Raltegravir

Indexed keywords

RALTEGRAVIR;

ARTICLE; DRUG DETERMINATION; DRUG IMPURITY; DRUG STRUCTURE; DRUG SYNTHESIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; SPECTROMETER; TANDEM MASS SPECTROMETRY;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DRUG CONTAMINATION; HIV INTEGRASE INHIBITORS; PYRROLIDINONES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 70349335353     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.08.007     Document Type: Article

References (12)

1. Federsel H.-J. Searching for scaleable processes: addressing the challenges in times of increasing complexity. Curr. Opin. Drug Disc. Dev. 6 (2003) 838-847
2. Hillier M.C., and Reider P.J. Stereoselective synthesis from a process research perspective. Drug Disc. Today 7 (2002) 303-314
3. Rubin A.E., Tummala S., Both D.A., Wang C., and Delaney E.J. Emerging technologies supporting chemical process R&D and their increasing impact on productivity in the pharmaceutical industry. Chem. Rev. 106 (2006) 2794-2810
4. Vuletic M., Cindric M., and Koruznjak J.D. Identification of unknown impurities in simvastatin drug substance and tablets by liquid chromatography/tandem mass spectrometry. J. Pharm. Biomed. Anal. 37 (2005) 715-721
5. Pace P., Spieser S.A.H., and Summa V. 4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 18 (2008) 3865-3869
6. Croxtall J.D., Lyseng-Williamson K.A., and Perry C.M. Raltegravir. Drugs 68 (2008) 131-138
7. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Paz O.G., Hazuda D.J., Jones P., Kinzel O., Laufer R., Monteagudo E., Muraglia E., Nizi E., Orvieto F., Pace P., Pescatore G., Scarpelli R., Stillmock K., Witmer M.V., and Rowley M. Discovery of raltegravir, a potent selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51 (2008) 5843-5855
8. Plumb R.S., Jones M.D., Rainville P., and Castro-Perez J.M. The rapid detection and identification of the impurities of simvastatin using high resolution sub 2 μm particle LC coupled to a hybrid time of flight MS operating with alternating high-low collision energy. J. Sep. Sci. 30 (2007) 2666-2675
9. Eckers C., Haskins N., and Langridge J. The use of liquid chromatography combined with a quadrupole time of flight analyzer for the identification of trace impurities in drug substance. Rapid Commun. Mass Spectrom. 11 (1997) 1916-1922
10. Long M.C., Bennetto-Hood C., and Acosta E.P. A sensitive HPLC-MS/MS method for the determination of raltegravir in human plasma. J. Chromatogr. B 867 (2008) 165-171
11. Merschman S.A., Vallano P.T., Wenning L.A., Matuszewski B.K., and Woolf E.J. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir) in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J. Chromatogr. B 857 (2007) 15-25
12. Poirier J.-M., Robidou P., and Jaillon P. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high performance liquid chromatography with fluorescence detection. J. Chromatogr. B 867 (2008) 277-281